Moogene Medi무진메디
322970 · KONEX · ₩322970 · 무진메디
- Market cap
- ₩18B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−52.6% from the high
₩1,701Today: ₩1,750 – ₩1,844₩3,790
Returns
- 1W−4.2%
- 1M−3.4%
- 3M−1.6%
- 6M−37.0%
- YTD−9.9%
- 1Y−6.9%
- Volume today
- 1,667
- 1.7× the 20-day average
- Traded today
- ₩3M
- Listed shares
- 10,085,689
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 52: heavy trading.
- MomentumFlat-3.9% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Moogene Medi stock overview
Moogene Medi (무진메디, KRX: 322970) is listed on KONEX, in the Biotech & Pharma sector. The company is a nano-medicine firm that develops lipid nanoparticle (LNP) delivery technology for drugs, including gene therapies, protein therapies and compound therapies. Its shares closed at ₩1,796 on Oct 30, 2026, down 2.66% on the day, giving it a market value of ₩18B.
Key facts
- Market cap
- ₩18B
- Sector
- Biotech & Pharma
- Latest price change
- −2.66%
- As of
- Oct 30, 2026
- Main business
- The company is a nano-medicine firm that develops lipid nanoparticle (LNP) delivery technology for drugs, including gene therapies, protein therapies and compound therapies.
Quick answers about Moogene Medi
- What does Moogene Medi do?
- The company is a nano-medicine firm that develops lipid nanoparticle (LNP) delivery technology for drugs, including gene therapies, protein therapies and compound therapies. It is developing cancer treatments for colorectal and pancreatic cancer, a topical hair-loss treatment that is in pre-clinical and clinical preparation with partner pharmaceutical companies, and functional cosmetics such as hair tonics and skin boosters, which it produces through contracted manufacturing. The company also licenses LNP materials and works on mRNA-LNP research with pharmaceutical and biotech partners.
- What is the market cap of Moogene Medi?
- The market capitalisation of Moogene Medi was ₩18B at the close on Oct 30, 2026.
- Who are the largest shareholders of Moogene Medi?
- According to the latest official filings, the largest reported holders are Yoon Tae-jong (25.62%, as of Nov 27, 2025); Kim Jin-hyeon (0.05%, as of Jan 6, 2025).
- When is the next earnings report from Moogene Medi?
- Korean companies rarely announce results dates in advance. Based on when Moogene Medi filed the same report in past years, its next annual results is expected between Mar 19, 2027 and Mar 23, 2027.
Company profile
The company is a nano-medicine firm that develops lipid nanoparticle (LNP) delivery technology for drugs, including gene therapies, protein therapies and compound therapies. It is developing cancer treatments for colorectal and pancreatic cancer, a topical hair-loss treatment that is in pre-clinical and clinical preparation with partner pharmaceutical companies, and functional cosmetics such as hair tonics and skin boosters, which it produces through contracted manufacturing. The company also licenses LNP materials and works on mRNA-LNP research with pharmaceutical and biotech partners.
Written by AI from the company's latest annual report.
- Korean name
- 무진메디
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 윤태종
- Founded
- Jun 2016
- Listed
- Jun 2020
- Listed shares
- 10,085,689
- Fiscal year ends
- Month 12
- Website
- www.moogene.com/
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- Investor relations (IR) eventOct 6, 2026
- Adjustment of Conversion Price (2nd Series)Sep 28, 2026
- Investor relations (IR) eventSep 18, 2026
- [Amended] Results of Securities Issuance (Voluntary Disclosure)Apr 2, 2026
- Amended: Convertible bond issue decisionApr 2, 2026
Titles in Korean until English translations are added.
Also known as: Moogene Medi / 무진메디 / 322970 / KRX:322970
Source: KRX statistical information